Shilpa Medicare Limited has announced the appointment of Dr. Vellaian Karuppiah as Chief Operating Officer (COO) - Formulations, effective 23 April 2026. The appointment has been duly approved by the Nomination and Remuneration Committee of the company and was disclosed under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Appointment Details

The appointment of Dr. Karuppiah as a Senior Managerial Personnel follows the prescribed regulatory requirements. The disclosure was made in compliance with SEBI Master Circular No. HO/49/14/14(7)2025-CFDPOD2/I/3762/2026 dated 30th January 2026. The key details of the appointment are outlined below:

Professional Background

Dr. Vellaian Karuppiah, aged 52 years, brings over 33 years of extensive and diverse experience across the pharmaceutical value chain. His expertise spans multiple critical areas including Formulation & Analytical R&D, Regulatory Affairs, Manufacturing Science & Technology (MS&T), Technology Transfer, Engineering & Projects, Quality Systems, EHS/ESG, Supply Chain Management, PPIC, and end-to-end Manufacturing Operations.

Throughout his career, Dr. Karuppiah has held senior leadership and C-suite positions in several globally reputed pharmaceutical organizations. His previous roles include positions at Gland Pharma Limited (Fosun Group), Strides Group, Dr. Reddy's Laboratories, Actavis (now Teva), and Orchid Healthcare (Hospira/Pfizer). Most recently, he served as Chief Operating Officer at Acme Group and Immacule Lifesciences.

Educational Qualifications

Dr. Karuppiah holds a Postgraduate degree and Doctorate in Pharmacy. Additionally, he has acquired Executive Management qualifications from premier Tier-1 institutions in India and abroad, further strengthening his strategic orientation and leadership capabilities.

Strategic Impact

The company expects that Dr. Karuppiah's proven leadership capabilities, strategic orientation, and rich industry experience will significantly strengthen Shilpa Medicare Limited's Formulation business operations. His appointment is anticipated to enhance operational efficiencies, improve manufacturing efficiency, strengthen supply chain resilience, and support long-term sustainable growth for the organization.

Shilpa Medicare Limited has announced the retirement of Dr. Jayant Karajgi, Chief Operating Officer - Formulations, effective 22 April 2026. The pharmaceutical company made this disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Key Details of the Retirement

The company informed both BSE Limited and National Stock Exchange of India Ltd about this senior management change. Dr. Karajgi retired from the services of the company with effect from closing hours of 22 April 2026.

Regulatory Compliance

The disclosure was made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Master Circular No. HO/49/14/14(7)2025-CFDPOD2/I/3762/2026 dated 30th January 2026. Consequently, Dr. Karajgi also ceased to be a Senior Management Personnel of the company from the same date.

Company Information

Shilpa Medicare Limited, with CIN L85110KA1987PLC008739, operates from its corporate office in Raichur, Karnataka. The company's shares are listed on both NSE (SHILPAMED) and BSE (530549). The disclosure was signed by Ritu Tiwary, Company Secretary & Compliance Officer, and submitted to the stock exchanges for information and records.